PV Bulletin

National Centre for Adverse Drug Reaction Monitoring Annual Report

The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has released its Annual Report detailing adverse drug reactions and safety monitoring activities.

Primary source: Cancellation of Notified Cosmetic Products

PV Impact Brief

Urgency: HighConfidence: high

What changed

The report includes specific causality verification processes conducted by the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) which determines safety profiles for registered drugs.

Why it matters

This report is crucial for informing healthcare professionals and the public about drug safety and the regulatory actions that NPRA may take, such as updating product information or restricting product use.

Action needed

Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 26, 2026

Full briefing

Practical implication

Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.

The NPRA issued an annual report outlining their activities in monitoring adverse drug reactions (ADRs) and adverse events following immunization (AEFIs) in Malaysia, providing insights into drug safety and regulatory measures.

What changed: The report includes specific causality verification processes conducted by the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) which determines safety profiles for registered drugs.

Why it matters: This report is crucial for informing healthcare professionals and the public about drug safety and the regulatory actions that NPRA may take, such as updating product information or restricting product use.

Practical implication: Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.

View original source

  • Source: NPRA (Malaysia) - Safety Alerts
  • Published at source: 2026-08-26T23:49:07.000Z
  • Discovered by monitor: 2026-08-26T23:49:46.866Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Reporting Requirement#Malaysia#Source-ingestion#Regulator-monitor#Npra.gov.my

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward